Researchers reported at the Journal of the American Medical Association for Internal Medicine that the symptoms of hot flashes and night sweating after menopause have improved significantly among women who eat non -hormonal pills produced by Bayer, are currently in an advanced stage of experiments.
More than 600 menstruating women took them and suffer from annoying vascular motor symptoms, either ANINGANTAN or an imaginary drug per day for 52 weeks.
The researchers stated that by the 12th week, the women who take the property of Einzanitant recorded a decrease of 73% in the frequency and severity of these symptoms, compared to a 47% decrease in the imaginary drug group.
By the 50th week, women in the Einzanitant group were on average from 1.4 hot to severe to a day, compared to 3.5 of these symptoms per day in the group that took the imaginary medicine.
It seemed that the medicine of Einzanitant reduces sleep disorders and improves the quality of life, but the study was not aimed at assessing these secondary benefits completely.
The researchers concluded that the drug had no harmful effects on the liver or bone density.
Nearly 30% of women receiving ANINGANTANT and 15% of women in the imaginary drug group have been the same as negative symptoms associated with treatment, such as headache and drowsiness.
“Not only confirmed this study, which lasted for a year, the initial conclusions on the rapid and significant decline in the frequency and intensity of hot flashes and night sweating, but also provided evidence that these effects continued for a year, which gives hope to reduce them for the long term,” said the chief study personnel, Dr. Joan Penkerton of the University of Virginia, in a statement.
“It is likely that the Einzanitant is an important addition to the group of non -hormonal drug options to treat vascular motor symptoms,” said in an editorial published with the results of the study.
The property was approved in July for use in the United Kingdom and Canada, where it is marketed in the name of Lincit, and the drug is still being reviewed by the US Food and Drug Administration.